|FROM ||Ruben Safir
|SUBJECT ||Subject: [NYLXS - HANGOUT] [email@example.com: ICS Prescription Formulary Coverage Change]
|From owner-hangout-outgoing-at-mrbrklyn.com Thu Mar 28 18:50:12 2013
Received: by mrbrklyn.com (Postfix)
id C76DC161C96; Thu, 28 Mar 2013 18:50:11 -0400 (EDT)
Received: by mrbrklyn.com (Postfix, from userid 28)
id B80C1161C99; Thu, 28 Mar 2013 18:50:11 -0400 (EDT)
Received: from mailbackend.panix.com (mailbackend.panix.com [18.104.22.168])
by mrbrklyn.com (Postfix) with ESMTP id 583D0161C96
for ; Thu, 28 Mar 2013 18:50:11 -0400 (EDT)
Received: from panix2.panix.com (panix2.panix.com [22.214.171.124])
by mailbackend.panix.com (Postfix) with ESMTP id 5A25A340A7
for ; Thu, 28 Mar 2013 18:50:10 -0400 (EDT)
Received: by panix2.panix.com (Postfix, from userid 20529)
id 469AA33C8C; Thu, 28 Mar 2013 18:50:10 -0400 (EDT)
Date: Thu, 28 Mar 2013 18:50:10 -0400
From: Ruben Safir
Subject: [NYLXS - HANGOUT] [info-at-rxinsider411.com: ICS Prescription Formulary Coverage Change]
Content-Type: text/plain; charset=us-ascii
User-Agent: Mutt/1.5.20 (2009-06-14)
Let us celebrate upon this urgent news from your insurance company!
----- Forwarded message from RXinsider 411 -----
Date: Thu, 28 Mar 2013 17:47:50 -0400
From: RXinsider 411
Subject: ICS Prescription Formulary Coverage Change
View this email online:
Rx FORMULARY COVERAGE CHANGE
EFFECTIVE JANUARY 1, 2013
Preferred Rx Formulary Coverage December January
by percent of covered lives 2012 2013
QVAR? 92% -> 92%
(belcomethasone dipropionate HFA)
Flovent? HFA 90% -> 67%
*QVAR is not the only agent in its class with Preferred Rx Formulary Status on Medco
and Express Scripts. Please review complete Rx Formulary Status at the PBM?s website.
MORE INSURED PATIENTS MAY PAY LESS FOR QVAR
QVAR (beclomethasone dipropionate HFA) Inhalation Aerosol is
indicated in the maintenance treatment of asthma as prophylactic
therapy in patients 5 years of age or older. QVAR is also
indicated for asthma patients who require systemic corticosteroid
administration, where adding QVAR may reduce or eliminate the need
for systemic corticosteroids.
Important Safety Information
? QVAR is not a bronchodilator and is not indicated for relief of
CAUTION: Adrenal insufficiency may occur when transferring patients
from systemic steroids (see WARNINGS, Prescribing Information).
? A reduction in growth velocity in growing children and teenagers
may occur as a result of inadequate control of chronic diseases
such as asthma or from use of corticosteroids for treatment.
? Common side effects associated with the use of QVAR and placebo
in clinical trials include, but are not limited to, headache
(12% and 9% respectively) and pharyngitis (8% and 4% respectively).
Please see full Prescribing Information.
REFERENCES: 1. Fingertip Formulary?. Glen Rock, NJ: Fingertip
Formulary, LLC; December 2012. 2. Fingertip Formulary?. Glen Rock,
NJ: Fingertip Formulary, LLC; January 2013.
QVAR? is a registered trademark of IVAX LLC, a member of the
Teva Group. The brands listed are the registered trademarks of
their respective owners. ?2013 Teva Respiratory, LLC. QVA-40016
We hope you found this message to be useful. However,
if you prefer not to receive future emails from us,
please visit http://rxinsider.net/users/opt_out.php
to discontinue service.
RXinsider | 1300 Division Rd | West Warwick | RI | 02893
----- End forwarded message -----